CapsoVision, Inc. (CV) AI Stock Analysis

• Market Cap: $235.15M
• Dividend Yield: N/A
• Average Volume (3M): 45.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): -0.17
• Shares Outstanding: 46,843,224
• 10 Day Avg. Volume: 21,973
• 30 Day Avg. Volume: 45,470
• PEG Ratio: 0.00
• Price to Book (P/B): -1.04
• Price to Sales (P/S): 11.50
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.50
• Price Target Upside: -20.63% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $5.00 ▼(-62.21% Downside)

The score is weighed down primarily by weak financial performance (losses, negative equity, and negative operating/free cash flow) and a bearish technical setup (below key moving averages with negative MACD). Positive FDA-related product/regulatory initiatives provide some upside, while valuation data is insufficient to materially improve the rating.

Positive Factors

FDA 510(k) submission for AI module

A 510(k) submission for an AI-assisted reading module is a structural product development that, if cleared, enables U.S. commercialization of workflow‑reducing software. Clearance would cement a scalable software offering that complements capsule sales and can sustainably improve adoption and unit economics.

Breakthrough Device Designation pursuit

Seeking Breakthrough Device status targets expedited development and regulatory engagement for early pancreatic cancer detection. If granted, it can shorten time-to-market, improve clinician adoption, and create a durable clinical differentiation addressing an unmet diagnostic need with potential long-term clinical and commercial implications.

Recurring consumable + software revenue model

A business model centered on disposable imaging capsules plus software and services creates recurring revenue potential and predictable unit demand. Over time, consumable-driven workflows can provide steady revenue streams and higher lifetime value per customer if clinical adoption and reimbursement trends hold.

Negative Factors

Negative stockholders' equity

Negative shareholders' equity is a durable solvency concern: it signals liabilities exceed assets, limits borrowing capacity, can constrain supplier and customer confidence, and reduces strategic flexibility. Without sustained profitability or capital support, growth and R&D programs are at persistent risk.

Negative operating and free cash flow

Persistent negative operating and free cash flow undermines the company's ability to self-fund commercialization and product development. Over months, continued cash burn increases dilution or financing dependency, complicates long-term planning, and raises execution risk for regulatory and commercial milestones.

Unprofitable with declining margins

Revenue growth paired with worsening margins and sizable losses indicates structural cost or pricing issues. If inefficiencies persist, the company may struggle to translate clinical/regulatory wins into sustainable profitability, requiring material operational restructuring or continued external capital over the medium term.

CapsoVision, Inc. Business Overview & Revenue Model

Company Description

CapsoVision, Inc. (CV) is a pioneering company in the medical technology sector, specializing in the development of innovative gastrointestinal imaging solutions. The company focuses on enhancing patient care through its flagship product, the CapsoCam, a capsule endoscopy system designed to provide high-quality images of the gastrointestinal tract with minimal discomfort for patients. CapsoVision aims to improve diagnostic capabilities and patient outcomes by leveraging advanced imaging technologies and a commitment to continuous innovation in the field of gastrointestinal health.

How the Company Makes Money

CapsoVision generates revenue primarily through the sale of its CapsoCam capsule endoscopy systems and related disposable products, such as the capsules used in procedures. The company also earns revenue from partnerships with healthcare providers and institutions, which may include training, support services, and bulk purchase agreements. Additionally, CapsoVision may explore collaborations with pharmaceutical companies for research and clinical trials, further diversifying its revenue streams. The company's business model is built on establishing a strong presence in hospitals and outpatient clinics, aiming to create long-term relationships that lead to repeat purchases and ongoing service contracts.

CapsoVision, Inc. Financial Statement Overview

Summary

Financials are weak: profitability is negative with declining EBIT/EBITDA margins, the balance sheet shows negative stockholders’ equity (solvency concern), and operating/free cash flow are negative, despite reported revenue growth.

Income Statement

CapsoVision, Inc. shows a concerning financial performance with negative net profit margins and declining EBIT and EBITDA margins. The company experienced a revenue growth of 20.5% from the previous year, but this was overshadowed by significant losses, indicating inefficiencies in cost management and operations.

Balance Sheet

The balance sheet reflects a negative stockholders' equity, which is a critical concern, indicating that liabilities exceed assets. The debt-to-equity ratio is negative due to the negative equity, and the return on equity is also negative, highlighting poor financial health and potential solvency issues.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, suggesting liquidity challenges. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income, but both are negative, which is a red flag for financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	9.64M	11.76M	9.75M
Gross Profit	5.22M	6.38M	5.49M
EBITDA	-17.53M	-19.40M	-10.96M
Net Income	-17.92M	-19.90M	-11.30M
Balance Sheet
Total Assets	―	16.80M	21.53M
Cash, Cash Equivalents and Short-Term Investments	―	9.32M	14.56M
Total Debt	―	1.24M	1.51M
Total Liabilities	―	146.31M	131.37M
Stockholders Equity	―	-129.51M	-109.84M
Cash Flow
Free Cash Flow	-15.26M	-20.24M	-11.56M
Operating Cash Flow	-15.18M	-20.09M	-10.80M
Investing Cash Flow	-82.00K	-153.00K	-754.00K
Financing Cash Flow	23.59M	15.07M	20.53M

CapsoVision, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	73 Outperform	$37.86B	29.28	20.62%	0.72%	6.73%	3.34%
NVST	69 Neutral	$3.86B	280.74	0.50%	―	4.73%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANGO	51 Neutral	$427.01M	-15.39	-15.26%	―	2.73%	87.03%
CV	44 Neutral	$235.15M	―	―	―	―	―

CapsoVision, Inc. Corporate Events

CapsoVision Seeks FDA Clearance for AI Endoscopy Module

On December 29, 2025, CapsoVision, Inc. announced it had submitted a 510(k) application to the U.S. Food and Drug Administration for an AI-assisted reading module for its CapsoCam Plus capsule endoscopy system, a move aimed at improving detection of clinically significant small bowel pathology and reducing clinician review time. The company positions the AI module, supported by an in-house AI capability, a large and growing imaging dataset, and a fully cloud-based architecture, as a differentiator versus competing capsule endoscopy systems, potentially enhancing workflow efficiency, diagnostic accuracy, and accessibility for gastrointestinal practices once regulatory clearance enables U.S. commercialization.

The most recent analyst rating on (CV) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Seeks FDA Breakthrough Status for CapsoCam

On November 10, 2025, CapsoVision announced the submission of an application to the FDA for Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system, aimed at early-stage pancreatic cancer detection. This non-invasive technology could significantly impact the early diagnosis of pancreatic ductal adenocarcinoma, one of the deadliest cancers, by providing a patient-friendly alternative to current invasive diagnostic methods. If granted, the designation would expedite the development process and potentially improve survival rates by enabling earlier detection and treatment.

The most recent analyst rating on (CV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

CapsoVision Appoints David Garcia as Finance VP

On November 3, 2025, CapsoVision, Inc. announced the appointment of David Garcia as its Senior Vice President of Finance, who will also serve as the principal financial officer and principal accounting officer. Mr. Garcia brings over 20 years of financial leadership experience, having previously worked at Matterport, Inc., View, Inc., Intelepeer Cloud Communications, and Align Technology. His appointment is seen as a strategic move to support CapsoVision’s growth and development pipeline, leveraging his expertise in financial management and capital markets.

The most recent analyst rating on (CV) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.